Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Bani-Sadr F, Goderel I, Lapidus N, Driss H, Simon A, Rosenthal E, Morand P, Lunel-Fabiani F, Pol S, Cacoub P, Perronne C, Carrat F; ANRS HC02 - RIBAVIC Study Team. Bani-Sadr F, et al. Among authors: perronne c. AIDS. 2008 Jul 11;22(11):1385-7. doi: 10.1097/QAD.0b013e328305bd8d. AIDS. 2008. PMID: 18580626 Free article. Clinical Trial. No abstract available.
Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.
Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, Degott C, Pol S; ANRS HC02 - Ribavic Study team. Bani-Sadr F, et al. Among authors: perronne c. AIDS. 2006 Feb 28;20(4):525-31. doi: 10.1097/01.aids.0000210606.63138.f5. AIDS. 2006. PMID: 16470116 Clinical Trial.
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, Pol S, Carrat F, Cacoub P; French National Agency for Research on AIDS; Viral Hepatitis-HC02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: perronne c. Clin Infect Dis. 2008 Mar 1;46(5):768-74. doi: 10.1086/527565. Clin Infect Dis. 2008. PMID: 18248298
Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapy.
Bani-Sadr F, Lapidus N, Rosenthal E, Gerard L, Foltzer A, Perronne C, Cacoub P, Pol S, Carrat F; ANRS HC02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: perronne c. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):429-30. doi: 10.1097/QAI.0b013e31819a2429. J Acquir Immune Defic Syndr. 2009. PMID: 19322037 Clinical Trial. No abstract available.
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team. Carrat F, et al. Among authors: perronne c. JAMA. 2004 Dec 15;292(23):2839-48. doi: 10.1001/jama.292.23.2839. JAMA. 2004. PMID: 15598915 Clinical Trial.
Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C; ANRS Hc02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: perronne c. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52. doi: 10.1097/01.qai.0000174649.51084.46. J Acquir Immune Defic Syndr. 2005. PMID: 16123681
296 results